Merck on the AIDS 2018 announces new data for doravirine
Merck announces week 96 data from pivotal Phase 3 drive-forward study of its investigational HIV therapy doravirine.
Merck announces week 96 data from pivotal Phase 3 drive-forward study of its investigational HIV therapy doravirine.